0 seconds of 2 minutes, 34 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
00:00
02:34
02:34
 
  • Algernon Pharmaceuticals has met the co-primary endpoint in its Phase 2 proof of concept study evaluating NP-120 for the treatment of idiopathic pulmonary fibrosis and chronic cough
  • Based on the positive data, the company plans to file a pre-IND application with the U.S. FDA for a Phase 2b IPF study
  • Christopher J. Moreau, CEO of Algernon Pharmaceuticals, sat down with Sabrina Cuthbert to discuss the update
  • Algernon is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds, for new disease applications
  • Algernon Pharmaceuticals Inc. (AGN) opened trading at C$3.17 per share

Algernon Pharmaceuticals (AGN) has met the co-primary endpoint in its Phase 2 proof of concept study evaluating NP-120 (Ifenprodil).

Ifenprodil is being evaluated for the potential treatment of idiopathic pulmonary fibrosis (“IPF”) and chronic cough.

Based on the positive data, the company plans to file a pre-IND application with the U.S. FDA for a Phase 2b IPF study. The Phase 2b study will also have multiple arms, multiple doses, would be placebo controlled and would be double blinded and randomized.

For chronic cough, Algernon has already filed a pre-IND application with the U.S. FDA and has announced that it has received positive feedback.

Christopher J. Moreau, CEO of Algernon Pharmaceuticals, sat down with Sabrina Cuthbert to discuss the update.

Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications.

Algernon Pharmaceuticals Inc. (AGN) opened trading at C$3.17.

More From The Market Online
AI generated stock image Canadian Maple Leaf on top of stock market graph, with people on the floor looking upward

@ the Bell: TSX starts week strong

The TSX kicked off the week with a strong rally, reflecting gains seen on Wall Street as the US might adopt a moderate tariff…
ai generated stock image.

@ the Bell: Did markets grow on the first day of spring?

TSX growth was driven by strong performances in the energy and financial sectors, supported by rising oil prices.
Stock image generated with AI

@ the Bell: TSX finishes Friday lower but higher on the week

ended lower on Friday, driven by a drop in mining stocks amid concerns about the impact of trade tariffs on economic growth.